Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 19/20 | 0.60 |
| ▸ | TDO2 | P48775 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17665332 | 0.99 | IDO1 (0.61) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL16135356 | 0.99 | IDO1 (0.61) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL17665331 | 0.99 | IDO1 (0.61) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL17665329 | 0.99 | IDO1 (0.61) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL17665330 | 0.99 | IDO1 (0.61) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL16135347 | 0.91 | TDO2 (0.55) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL16135374 | 0.89 | TDO2 (0.53) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL16135337 | 0.87 | TDO2 (0.51) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL17665472 | 0.86 | IDO1 (0.47) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL16135345 | 0.85 | TDO2 (0.52) | IDO1TDO2CYP3A4CYP2D6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366678-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | Newlink Genetics Corporation (US) | 2018-08-29 | — | — | EP | claimed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | claimed |
| EP-2976332-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION. | NEWLINK GENETICS CORP (US) | 2018-01-31 | — | — | EP | claimed |
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2017-09-14 | — | — | US | claimed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | claimed |
| EP-3366678-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | Newlink Genetics Corporation (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2976332-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION. | NEWLINK GENETICS CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-2976332-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION. | NEWLINK GENETICS CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160060266-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2016-03-03 | — | — | US | disclosed |
| US-20160060266-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2016-03-03 | — | — | US | disclosed |
| US-20160060266-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2016-03-03 | — | — | US | disclosed |
| WO-2014159248-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | NEWLINK GENETICS CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | IDO1, IDO2, TDO2 | IDO1 1/4885TDO2 3/4885CYP3A4 142/4885 |
| US-20160060266-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | IDO1, IDO2, TDO2 | IDO1 1/4885TDO2 3/4885CYP3A4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.